Lv1
28 积分 2024-03-18 加入
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
4天前
已完结
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study
4天前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
8天前
已完结
TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells
1个月前
已完结
Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer
1个月前
已完结
Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models
2个月前
已完结
Site‐Specific Polyplex on CCR7 Down‐Regulation and T Cell Elevation for Lymphatic Metastasis Blocking on Breast Cancer
5个月前
已完结
How chemokines organize the tumour microenvironment
5个月前
已完结
Human ILC2s can act as cytolytic killers
5个月前
已关闭
A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
6个月前
已完结
皖公网安备34019202002308
